Clinical trials: Locoregionally Advanced Nasopharyngeal Carcinoma
Nasopharyngeal Carcinoma
Two Cycles Versus Three Cyclle of CCRT for Low Risk Locoregionally Advanced Nasopharyngeal Carcinoma
This is a Phase II trial to study the effectiveness of two cycles versus three cycles of Concurrent Chemoradiotherapy in treating patients with Low Risk Locoregionally Advanced Nasopharyngeal Carcinoma based on pretreatment…
- Trial name
- NCT02871518
- Testing
- Cisplatin combine with IMRT
- Where
- China
- Volunteers
- 236 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Reduced Target Delineation and Radiation Doses Chemoradiotherapy for Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
To determine the efficacy and safety of sequential chemoradiotherapy with regimen of docetaxel, cisplatin and fluorouracil and reduced target delineation and radiation doses IMRT for patients with locoregionally advanced…
- Trial name
- NCT03389295
- Testing
- Reduced Target Delineation and Radiation Doses
- Where
- China
- Volunteers
- 118 people
- Sponsor
- Xiayun He, MD
Nasopharyngeal Carcinoma
A Multicenter Trial Evaluating the Efficacy of Nedaplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
This study is a multicenter trial.The primary objective is to estimate short-term efficacy and acute toxicities of nedaplatin to the combination of docetaxel in neoadjuvant chemotherapy followed by nedaplatin in concurrent…
- Trial name
- NCT01479504
- Testing
- nedaplatin and docetaxel, cisplatin and docetaxel
- Where
- China
- Volunteers
- 2 people
- Sponsor
- Guangxi Medical University
Nasopharyngeal Carcinoma
PD-1 Blockade and Bevacizumab Replace Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma
At present, the treatment regimen of locally advanced nasopharyngeal carcinoma still needs to be further improved, and the focus of improvement lies in "replacing cisplatin with high-efficiency and low-toxicity treatment…
- Trial name
- NCT05341193
- Testing
- Bevacizumab+Toripalimab+gemcitabine, adjuvant with Bevacizumab and Toripalimab, Bevacizumab+Toripalimab+gemcitabine, adjuvant with Toripalimab
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal Carcinoma
This randomized clinical trial determining whether Sintilimab plus Capecitabine versus Capecitabine alone can improve the progression-free survival rate of NPC patients with unfavorable response to induction chemotherapy.
- Trial name
- NCT05201859
- Testing
- Sintilimab, Capecitabine
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma, De-escalation Therapy
Under Whole-course of Immunotherapy, Gradient Fractionated RT with CCT Versus CFRT with CCT for LANPC Who Achieved PR Post Induction Chemotherapy.
This prospective trial aims to enroll patients with stage III-IVA (AJCC 8th,) locoregionally advanced nasopharyngeal carcinoma (LANPC).
- Trial name
- NCT06675214
- Testing
- Full course of PD-1/PD-L1 blockades, Cisplatin-based induction chemotherapy, Standard-dose IMRT
- Where
- China
- Volunteers
- 586 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Umbrella Biomarker-Guided Therapy in NPC
This is a phase 2, open-label, umbrella study, with the purpose to evaluate the therapeutic efficacy and safety of chemoradiotherapy in combination with immunotherapy and/or targeted treatment in high-risk locoregionally advanced…
- Trial name
- NCT04605562
- Testing
- GP+DDP, Palbociclib, Intensity-modulated radiotherapy
- Where
- China
- Volunteers
- 206 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Induction Chemotherapy Followed by IMRT or Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
In the era of comprehensive therapy, many studies have investigated the value of induction chemotherapy (IC) in the treatment of nasopharyngeal carcinoma (NPC).
- Trial name
- NCT05527470
- Testing
- Gemcitabine,Cisplatin, Intensity-modulated radiation therapy (IMRT), Cisplatin
- Where
- 2 sites in China
- Volunteers
- 440 people
- Sponsor
- Wei Jiang
Nasopharyngeal Carcinoma, Neoadjuvant Therapy
PD-1 Inhibitor Plus GP as Neoadjuvant Therapy for Locoregionally Advanced Nasopharyngeal Carcinoma
The purpose of this Phase II, Multicenter, Randomized Controlled Clinical Trial is to evaluate the efficacy and safety of PD-1 inhibitor Plus GP chemotherapy as Neoadjuvant Therapy in the Treatment of Locoregionally Advanced…
- Conditions
- Nasopharyngeal Carcinoma, Neoadjuvant Therapy, PD-1 Inhibitor
- Trial name
- NeoTurbo (NCT05340270)
- Testing
- PD-1 inhibitor+GP, GP
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Guangxi Medical University
Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer
Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma
This trial aim to explore whether short-course tislelizumab (3 cycles of 200 mg q3w in the induction phase and 3 cycles of 400 mg q6w in the consolidation phase) yields non-inferior event-free survival compared to long-course…
- Trial name
- NCT07373990
- Testing
- tislelizumab, Gemcitabine + cisplatin (GP), Cisplatin (100mg/m2)
- Volunteers
- 418 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Nedaplatin Versus Cisplatin and Capecitabine Versus Fluorouracil in IC + CCRT for Locoregionally Advanced NPC
This is a phase 3, multicentre, non-inferiority, randomised factorial trial. The purpose of this study is to study the efficacy and safety of nedaplatin versus cisplatin, and capecitabine versus fluorouracil in induction…
- Trial name
- NX-NPC (NCT03503136)
- Testing
- docetaxel, nedaplatin, and capecitabine, nedaplatin, docetaxel, cisplatin, and fluorouracil
- Where
- China
- Volunteers
- 632 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
The Role of Induction Gemcitabine and Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma in the Era of IMRT
The purpose of this study is to verify that induction gemcitabine and cisplatin plus intensity-modulated radiotherapy (IMRT) is non-inferior to concurrent weekly cisplatin plus IMRT for patients with locoregionally advanced…
- Trial name
- NCT02460887
- Testing
- Gemcitabine, cisplatin, Intensity-modulated Radiotherapy
- Where
- China
- Volunteers
- 236 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
This is a Phase II Randomized Trial to Compare Paclitaxel combined with DDP Plus Concurrent Chemoradiotherapy With DDP Plus Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
- Trial name
- NCT03047265
- Testing
- Paclitaxel, Cisplatin
- Where
- China
- Volunteers
- 164 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Cancinoma (NPC)
Risk-Adapted Anlotinib and PD-L1 for Locoregionally Advanced Nasopharyngeal Carcinoma
The purpose of this study is to evaluate the efficacy and safety of a risk-adapted treatment strategy incorporating induction therapy (Gemcitabine + Cisplatin) with Anlotinib plus Benmelstobart, followed by treatment allocation…
- Trial name
- RAPID (NCT07904819)
- Testing
- Anlotinib Hydrochloride Capsules, Benmelstobart, Gemcitabine (GEM)
- Volunteers
- 214 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Induction Gemcitabine and Cisplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
The purpose of this study is to compare induction chemotherapy (gemcitabine+cisplatin) plus concurrent chemoradiotherapy (CCRT) with CCRT alone in patients with locoregionally advanced nasopharyngeal carcinoma(NPC), in order to…
- Trial name
- NCT01872962
- Testing
- gemcitabine and cisplatin (Induction chemotherapy), IMRT and concurrent cisplatin
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Concurrent Chemoradiation and Durvalumab for Locoregionally Advanced Nasopharyngeal Carcinoma
The investigators propose a phase II randomized-controlled study on using durvalumab in combination with induction chemotherapy followed by concurrent chemoradiation and adjuvant durvalumab, compared to induction chemotherapy…
- Trial name
- NCT04447612
- Testing
- Durvalumab, Cisplatin, Gemcitabine
- Where
- Hong Kong
- Volunteers
- 118 people
- Sponsor
- The University of Hong Kong
Nasopharyngeal Carcinoma, Nasopharyngeal Cancer
A Study of Cemiplimab and Fianlimab in People With Nasopharyngeal Carcinoma
The purpose of this study is to find out whether cemiplimab, with or without fianlimab, is an effective treatment for advanced nasopharyngeal carcinoma (NPC), when given with standard chemotherapy drugs gemcitabine and cisplatin…
- Conditions
- Nasopharyngeal Carcinoma, Nasopharyngeal Cancer, Nasopharynx Carcinoma, Nasopharynx Cancer
- Trial name
- NCT07650266
- Testing
- Cemiplimab, Fianlimab
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Recurrent Nasopharyngeal Undifferentiated Carcinoma, Stage IV Nasopharyngeal Undifferentiated Carcinoma
Cyclophosphamide for Nasopharyngeal Carcinoma
There is no standard third-line systemic treatment for inoperable locoregionally advanced recurrent or metastatic nasopharyngeal carcinoma (NPC).
- Trial name
- NCT02794077
- Testing
- Cyclophosphamide
- Volunteers
- 56 people
- Sponsor
- The University of Hong Kong
Nasopharyngeal Carcinoma, Induction Chemotherapy
Reducing Target Volumes in NPC Treated With Induction Chemotherapy Followed by Concurrent Chemoradiotherapy
To evaluate the long-term locoregional control, survival rate, late toxicity and quality of life after reducing the target volume in patients with locoregionally advanced nasopharyngeal carcinoma patients treated with induction…
- Conditions
- Nasopharyngeal Carcinoma, Induction Chemotherapy, Radiotherapy
- Trial name
- NPC-GTV (NCT04384627)
- Testing
- Delineating the GTV according to the pretreatment or post-IC tumor extension
- Where
- 2 sites in China
- Volunteers
- 445 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma (NPC)
Ivonescimab Combined With Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma
This trial aims to study the role of Ivonescimab combined with chemoradiotherapy in high-Risk locoregionally advanced nasopharyngeal carcinoma.
- Trial name
- NCT07064902
- Testing
- Ivonescimab（AK112，a PD-1/VEGF bispecific antibody）
- Where
- 3 sites in China
- Volunteers
- 48 people
- Sponsor
- Sun Yat-sen University